The only potential beneficial parameters detected were related to pathogen localization: fewer VIP treated mice tended to have systemic infection (2/12) compared to the non-treated infected mice (3/7), and the amount of C. rodentium in contact with epithelial cells tended to be lower in VIP treated mice compared to non-treated infected mice. The gene discussed is VIP; the disease is infection.